Revlimid
Payments companies reported to CMS as associated with Revlimid. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Revlimid, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Revlimid
These are the largest totals companies reported as associated with Revlimid. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Amer Zeidan | New Haven, CT | Hematology & Oncology | $1,695.40 |
| Jaroslaw Maciejewski | Cleveland, OH | Hematology (Internal Medicine) | $1,500.00 |
| Kenneth Anderson | Boston, MA | Medical Oncology | $316.00 |
| Brian Durie | West Hollywood, CA | Hematology & Oncology | $316.00 |
| Peter Voorhees | Charlotte, NC | Hematology (Internal Medicine) | $316.00 |
| Paul Richardson | Boston, MA | Hematology & Oncology | $316.00 |
| Jacob Laubach | Boston, MA | Medical Oncology | $316.00 |
| Sagar Lonial | Atlanta, GA | Hematology (Internal Medicine) | $316.00 |
| Angela Dispenzieri | Rochester, MN | Hematology (Internal Medicine) | $316.00 |
| Elizabeth Odonnell | Boston, MA | Internal Medicine | $316.00 |
Prescribed Revlimid?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.